MiNK Therapeutics, Inc.(INKT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

INKT MiNK Therapeutics, Inc.

Market Closed 04-10 16:00:00 EDT

11.04

-0.43

-3.75%

盘后11.44

+0.40+3.62%

19:42 EDT

High11.60	Low11.00	Vol21.53K
Open11.49	D1 Closing11.47	Amplitude5.23%
Mkt Cap54.82M	Tradable Cap18.51M	Total Shares4.97M
T/O243.33K	T/O Rate1.28%	Tradable Shares1.68M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"INKT","market":"US","secType":"STK","nameCN":"MiNK Therapeutics, Inc.","latestPrice":11.04,"timestamp":1775851200000,"preClose":11.47,"halted":0,"volume":21532,"hourTrading":{"tag":"盘后","latestPrice":11.44,"preClose":11.04,"latestTime":"19:42 EDT","volume":715,"amount":8118.23,"timestamp":1775864568286,"change":0.4,"changeRate":0.036232,"amplitude":0.036232},"delay":0,"changeRate":-0.037489102005231166,"floatShares":1677000,"shares":4965858,"eps":-2.925734,"marketStatus":"Market Closed","change":-0.43,"latestTime":"04-10 16:00:00 EDT","open":11.49,"high":11.6,"low":11,"amount":243329.729944,"amplitude":0.05231,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.925734,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1776067200000},"marketStatusCode":7,"adr":0,"listingDate":1634270400000,"exchange":"NASDAQ","adjPreClose":11.47,"preHourTrading":{"tag":"盘前","latestPrice":11.8597,"preClose":11.47,"latestTime":"09:11 EDT","volume":97,"amount":1147.246063,"timestamp":1775826664459,"change":0.3897,"changeRate":0.033976,"amplitude":0.011238},"postHourTrading":{"tag":"盘后","latestPrice":11.44,"preClose":11.04,"latestTime":"19:42 EDT","volume":715,"amount":8118.23,"timestamp":1775864568286,"change":0.4,"changeRate":0.036232,"amplitude":0.036232},"volumeRatio":0.4626834994892392},"requestUrl":"/m/hq/s/INKT/wiki","defaultTab":"wiki","newsList":[{"id":"2626013099","title":"Mink Therapeutics files Form 3 for Principal Financial Officer Melissa Orilall","url":"https://stock-news.laohu8.com/highlight/detail?id=2626013099","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626013099?lang=en_us&edition=fundamental","pubTime":"2026-04-10 04:16","pubTimestamp":1775765780,"startTime":"0","endTime":"0","summary":"Mink Therapeutics Principal Financial Officer Melissa Orilall filed an initial Form 3.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mink Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 09, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260409:nNDL4sVjFw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624865299","title":"Agenus to present Phase II BOT+BAL plus agenT-797 data in PD-1 refractory GEC at AACR","url":"https://stock-news.laohu8.com/highlight/detail?id=2624865299","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624865299?lang=en_us&edition=fundamental","pubTime":"2026-04-03 19:30","pubTimestamp":1775215825,"startTime":"0","endTime":"0","summary":"Agenus flagged new Phase II trial data in PD-1 refractory gastroesophageal cancer for future presentation at AACR 2026.Study evaluates botensilimab with balstilimab alongside MiNK Therapeutics’ allogeneic iNKT cell therapy agenT-797.Update targets checkpoint-inhibitor resistant disease, a setting where treatment options remain limited.Presentation scheduled for April 20, 2026, during AACR Annual Meeting in San Diego.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire  on April 03, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260403:nNDL4qCGV4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INKT","AGEN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624055105","title":"MiNK Therapeutics’ agenT-797 iNKT cell therapy data accepted for ASGCT 2026 presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2624055105","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624055105?lang=en_us&edition=fundamental","pubTime":"2026-04-02 19:30","pubTimestamp":1775129444,"startTime":"0","endTime":"0","summary":"MiNK Therapeutics flagged new data from its investigational allo-iNKT cell therapy, agenT-797, for presentation at ASGCT Annual Meeting on May 11-15, 2026.Planned presentation highlights context-dependent activity, pointing to adaptive immune modulation across cancer and ARDS settings without disclosing technical performance metrics.Update positions agenT-797 as a platform asset with potential to support development in both oncology and immune-mediated disease.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260402:nNDL3SrHjW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","INKT","NDAQ","IE00BKPKM429.USD","IE00BN0W2W23.USD","LU2095319765.USD","BK4588","BK4139","LU2210150020.SGD","BK4585","LU2210149790.SGD","SG9999014039.USD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","SG9999014021.USD","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","LU0314104364.USD","BK4112","SG9999014005.SGD","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624518333","title":"MiNK Therapeutics Price Target Maintained With a $35.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2624518333","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624518333?lang=en_us&edition=fundamental","pubTime":"2026-04-01 19:35","pubTimestamp":1775043300,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/INKT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 01, 2026 07:35 ET (11:35 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624590053","title":"Mink Therapeutics to present agenT-797 combination therapy abstract at ATS conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2624590053","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624590053?lang=en_us&edition=fundamental","pubTime":"2026-04-01 19:31","pubTimestamp":1775043099,"startTime":"0","endTime":"0","summary":"Mink Therapeutics to present poster on agenT-797 combination immunotherapy at American Thoracic Society 2026 International Conference, May 15-20, 2026, in Orlando, Florida.Poster presentation scheduled for May 20, 2026, 11:00 AM-1:00 PM EDT.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nNDL6nbGzy:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00BN0W2W23.USD","SG9999014021.USD","LU2095319765.USD","IE00BN0W2T93.GBP","LU0314104364.USD","NDAQ","IE00B3QW5Z07.USD","INKT","BK4112","LU2210149790.SGD","BK4139","LU2210150020.SGD","SG9999014005.SGD","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","IE00BKPKM429.USD","BK4585","SG9999014013.SGD","SG9999014039.USD","IE00B64PRP62.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624518375","title":"MiNK Therapeutics Announces Abstract Acceptance for Presentation at the American Thoracic Society (ATS) 2026 International Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2624518375","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624518375?lang=en_us&edition=fundamental","pubTime":"2026-04-01 19:30","pubTimestamp":1775043000,"startTime":"0","endTime":"0","summary":"NEW YORK, April  01, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc.(NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (allo-iNKT) cell therap","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/01/3266508/0/en/MiNK-Therapeutics-Announces-Abstract-Acceptance-for-Presentation-at-the-American-Thoracic-Society-ATS-2026-International-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4161","INKT","AFG","BK4117","ATS","BK4107"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624594079","title":"MiNK Therapeutics: Buy Rating on Emerging Pulmonary Franchise and Key agenT-797 ARDS Catalyst","url":"https://stock-news.laohu8.com/highlight/detail?id=2624594079","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624594079?lang=en_us&edition=fundamental","pubTime":"2026-04-01 18:15","pubTimestamp":1775038526,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on MiNK Therapeutics today and set a price target of $35.00. Emily Bodnar has given hi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/mink-therapeutics-buy-rating-on-emerging-pulmonary-franchise-and-key-agent-797-ards-catalyst-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/mink-therapeutics-buy-rating-on-emerging-pulmonary-franchise-and-key-agent-797-ards-catalyst-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["INKT","ARDS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624954085","title":"Mink Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2624954085","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624954085?lang=en_us&edition=fundamental","pubTime":"2026-04-01 16:40","pubTimestamp":1775032817,"startTime":"0","endTime":"0","summary":"Mink Therapeutics Inc reports results for the quarter ended December 31 - Earnings SummaryMink Therapeutics Inc INKT.OQ reported a quarterly adjusted loss of 56 cents per share for the quarter ended D","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260401:nL8N40K0L5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623585164","title":"Mink Therapeutics Q4 EPS USD -0.56","url":"https://stock-news.laohu8.com/highlight/detail?id=2623585164","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623585164?lang=en_us&edition=fundamental","pubTime":"2026-03-31 19:31","pubTimestamp":1774956688,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nPLX4C462A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623585152","title":"MiNK Therapeutics Q4 EPS $(0.56) Beats $(0.82) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2623585152","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623585152?lang=en_us&edition=fundamental","pubTime":"2026-03-31 19:30","pubTimestamp":1774956653,"startTime":"0","endTime":"0","summary":"MiNK Therapeutics Q4 EPS $(0.56) Beats $(0.82) Estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51562975/mink-therapeutics-q4-eps-0-56-beats-0-82-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623585143","title":"Press Release: MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2623585143","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623585143?lang=en_us&edition=fundamental","pubTime":"2026-03-31 19:30","pubTimestamp":1774956600,"startTime":"0","endTime":"0","summary":"-- ARDS / hypoxemic pneumonia Phase 2 trial initiation 1H 2026; early data. by year end; market opportunity of 200,000--300,000 patients annually in. -- C-Further Consortium collaboration adds to growing non-dilutive funding. -- NIH STTR grant and Mary Gooze philanthropic award fully fund. -- Keystone Symposia data report iNKT depletion in end-stage Pulmonary. Terese Hammond, MD, Head of Pulmonary and Inflammatory Diseases at MiNK, added: \"There is a clear continuum from acute inflammation and autoimmune dysregulation to chronic fibrotic diseases like IPF and even immune-resistant cancers. MiNK's iNKT platform is uniquely suited to address this spectrum because of its ability to deliver context-dependent immune modulation -- activating anti-tumor responses in cancer while restoring balance and suppressing harmful inflammation in acute and chronic lung disease.\". agenT-797 advances in randomized Phase 2 in hypoxemic pneumonia/ARDS, a severe inflammatory condition affecting 200,000--300,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Press Release: MiNK Therapeutics Reports Q4 and Full Year 2025 Results; Phase 2 Programs Advance with Impactful Non-Dilutive Momentum","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622872991","title":"MiNK Therapeutics Explores Strategic Partnerships and Trial Collaborations","url":"https://stock-news.laohu8.com/highlight/detail?id=2622872991","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622872991?lang=en_us&edition=fundamental","pubTime":"2026-03-28 02:09","pubTimestamp":1774634991,"startTime":"0","endTime":"0","summary":"MiNK Therapeutics ( ($INKT) ) has issued an announcement. In response to recent investor inquiries, MiNK Therapeutics clarified that it is in activ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mink-therapeutics-explores-strategic-partnerships-and-trial-collaborations?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mink-therapeutics-explores-strategic-partnerships-and-trial-collaborations?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","INKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622875137","title":"BRIEF-Mink Therapeutics Says Co Discussing Potential Combination Trials & Strategic Minority Investments","url":"https://stock-news.laohu8.com/highlight/detail?id=2622875137","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622875137?lang=en_us&edition=fundamental","pubTime":"2026-03-27 23:28","pubTimestamp":1774625289,"startTime":"0","endTime":"0","summary":"BRIEF-Mink Therapeutics Says Co Discussing Potential Combination Trials & Strategic Minority Investments March 27  - Mink Therapeutics Inc INKT.O:MINK THERAPEUTICS INC - IN DISCUSSIONS FOR POTENTIAL COMBINATION TRIALS AND STRATEGIC MINORITY INVESTMENTS - SEC FILINGMINK THERAPEUTICS: IN DISCUSSIONS WITH MULTIPLE PARTIES REGARDING POTENTIAL COMBINATION TRIALS INVOLVING AGENT-797MINK THERAPEUTICS INC - HAS NOT PUBLICLY DISCLOSED ANY BINDING ARRANGEMENTS FOR COMBINATION TRIALS OR STRATEGIC INVESTMENTS - SEC FILINGSource text: [ID:n0001193125-26-127931]Further company coverage: INKT.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nFWN40F0SJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622418878","title":"Mink Therapeutics clarifies talks on agenT-797 combination trials; says no binding arrangements disclosed","url":"https://stock-news.laohu8.com/highlight/detail?id=2622418878","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622418878?lang=en_us&edition=fundamental","pubTime":"2026-03-27 22:42","pubTimestamp":1774622526,"startTime":"0","endTime":"0","summary":"Mink Therapeutics said it issued a clarification after investor inquiries about third-party postings on potential combination trials involving agenT-797.Discussions are ongoing with multiple parties about potential combination trials and possible strategic minority investments.The company said it has not disclosed any binding arrangements related to these potential trials or investments.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mink Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 27, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nNDL52LwZ3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622878487","title":"Mink Therapeutics Inc - in Discussions for Potential Combination Trials and Strategic Minority Investments - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2622878487","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622878487?lang=en_us&edition=fundamental","pubTime":"2026-03-27 22:41","pubTimestamp":1774622491,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nFWN40F0SJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","INKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622782226","title":"Mink Therapeutics Inc  expected to post a loss of 82 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2622782226","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622782226?lang=en_us&edition=fundamental","pubTime":"2026-03-27 21:36","pubTimestamp":1774618568,"startTime":"0","endTime":"0","summary":"Mink Therapeutics Inc  expected to post a loss of82cents a share - Earnings Preview Mink Therapeutics Inc INKT.OQ INKT.O is expected to  show no change in quarterly revenue when it reports  results on","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260327:nL8N40F18J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621114084","title":"Mink Therapeutics files initial beneficial ownership statement for Principal Accounting Officer Austin Charette","url":"https://stock-news.laohu8.com/highlight/detail?id=2621114084","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621114084?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:30","pubTimestamp":1774297848,"startTime":"0","endTime":"0","summary":"Austin Charette, principal accounting officer at Mink Therapeutics, filed an initial statement of beneficial ownership reporting 40 shares of common stock held directly.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mink Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 23, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL29rDCd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","INKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620027410","title":"MiNK Therapeutics Appoints New Principal Financial and Accounting Officers","url":"https://stock-news.laohu8.com/highlight/detail?id=2620027410","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620027410?lang=en_us&edition=fundamental","pubTime":"2026-03-20 05:59","pubTimestamp":1773957589,"startTime":"0","endTime":"0","summary":"MiNK Therapeutics ( ($INKT) ) has issued an announcement. On March 13, 2026, MiNK Therapeutics appointed Melissa Orilall, currently Vice President ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mink-therapeutics-appoints-new-principal-financial-and-accounting-officers?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mink-therapeutics-appoints-new-principal-financial-and-accounting-officers?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4139","BK4534","BK4588","PFG","BK4566","LU1989772923.USD","LU1989772840.SGD","BK4162","INKT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620271710","title":"Mink Therapeutics Inc - Appoints Melissa Orilall as Principal Financial Officer Effective March 13, 2026 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2620271710","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620271710?lang=en_us&edition=fundamental","pubTime":"2026-03-20 05:23","pubTimestamp":1773955398,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nFWN4070UG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["INKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620427179","title":"Mink Therapeutics names Melissa Orilall principal financial officer and Austin Charette principal accounting officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2620427179","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620427179?lang=en_us&edition=fundamental","pubTime":"2026-03-20 05:22","pubTimestamp":1773955325,"startTime":"0","endTime":"0","summary":"Mink Therapeutics appointed Melissa Orilall as Principal Financial Officer, effective March 13, 2026.Orilall is Vice President, Global Financial Operations at Agenus and previously worked at Whitehead Institute for Biomedical Research and in corporate banking.Austin Charette was appointed Principal Accounting Officer, effective March 13, 2026.Charette is Senior Director, Financial Reporting and Compliance at Agenus and previously worked at Deloitte & Touche.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mink Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 19, 2026","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL6NqBZB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGEN","INKT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.minktherapeutics.com;investor.minktherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0327},{"period":"1month","weight":-0.0125},{"period":"3month","weight":-0.1097},{"period":"6month","weight":-0.2114},{"period":"1year","weight":0.4565},{"period":"ytd","weight":-0.0099}],"compareEarnings":[{"period":"1week","weight":0.036},{"period":"1month","weight":0.0046},{"period":"3month","weight":-0.021},{"period":"6month","weight":0.0405},{"period":"1year","weight":0.2952},{"period":"ytd","weight":-0.0036}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company has a collaboration with autonomous therapeutics, inc. to develop novel therapies targeting metastatic tumors. The company was formerly known as AgenTus Therapeutics, Inc. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.041395},{"month":2,"riseRate":0.2,"avgChangeRate":-0.047548},{"month":3,"riseRate":0,"avgChangeRate":-0.079206},{"month":4,"riseRate":0.4,"avgChangeRate":-0.011794},{"month":5,"riseRate":0,"avgChangeRate":-0.100407},{"month":6,"riseRate":0.5,"avgChangeRate":0.033071},{"month":7,"riseRate":0.25,"avgChangeRate":0.215487},{"month":8,"riseRate":0.25,"avgChangeRate":0.146012},{"month":9,"riseRate":0,"avgChangeRate":-0.132506},{"month":10,"riseRate":0.5,"avgChangeRate":-0.021174},{"month":11,"riseRate":0.6,"avgChangeRate":-0.066406},{"month":12,"riseRate":0.4,"avgChangeRate":-0.119867}],"exchange":"NASDAQ","name":"MiNK Therapeutics, Inc.","nameEN":"MiNK Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"MiNK Therapeutics, Inc.(INKT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest MiNK Therapeutics, Inc.(INKT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"MiNK Therapeutics, Inc.,INKT,MiNK Therapeutics, Inc.股票,MiNK Therapeutics, Inc.股票老虎,MiNK Therapeutics, Inc.股票老虎国际,MiNK Therapeutics, Inc.行情,MiNK Therapeutics, Inc.股票行情,MiNK Therapeutics, Inc.股价,MiNK Therapeutics, Inc.股市,MiNK Therapeutics, Inc.股票价格,MiNK Therapeutics, Inc.股票交易,MiNK Therapeutics, Inc.股票购买,MiNK Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"MiNK Therapeutics, Inc.(INKT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest MiNK Therapeutics, Inc.(INKT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction